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Summary
High-dose methotrexate (HD-MTX) plays an important role in the consoli-
dation therapy of acute lymphoblastic leukaemia (ALL) in many treatment
regimens worldwide. However, there is a large interpatient variability in the
pharmacokinetics and toxicity of the drug. We investigated the influence of
single nucleotide polymorphisms (SNPs) in genes of the folate metabolic
pathway, transporter molecules and transcription proteins on the pharma-
cokinetics and toxicity of MTX and 7-hydroxy-methotrexate (7-OH-MTX).
63 SNPs of 14 genes were genotyped and a total of 463 HD-MTX courses
(administered according to the ALL-BFM 95 and ALL IC-BFM 2002 proto-
cols) were analysed. Haematological, hepatic and renal toxicities, estimated
by routine laboratory parameters were evaluated. Random forest and
regression trees were used for variable selection and model building. Linear
mixed models were established to prove the significance of the selected
variables. SNPs (rs4948502, rs4948496, rs4948487) of the ARID5B gene
were associated with the serum levels of MTX (P < 002), serum levels and
area under the curve of 7-OH-MTX (P < 002) and with hypoproteinaemia
(P = 0004). SLCO1B1 rs4149056 also showed a significant association with
serum MTX levels (P < 0001). Our findings confirm the association of
novel genetic variations in folate-related and ARID5B genes with the serum
MTX levels and acute toxicity.
Keywords: methotrexate, 7-hydroxy-methotrexate, acute lymphoblastic leu-
kaemia, ARID5B, pharmacogenetics.
Methotrexate (MTX) is a widely used anticancer agent that
plays an important role in the treatment of childhood malig-
nancies. Intravenous high-dose MTX (HD-MTX) with folinic
acid rescue is a key component of the consolidation therapy
of childhood acute lymphoblastic leukaemia (ALL) (Moricke
et al, 2008). The pharmacokinetics and pharmacodynamics
of the drug show large interpatient variability even with the
same treatment protocol (Schmiegelow, 2009; Mikkelsen
et al, 2011; Csordas et al, 2013). This diversity can be partly
explained by genomic alterations (mainly single nucleotide
polymorphisms, SNPs) in genes involved in the MTX
absorption, metabolism, excretion, cellular transport and
effector targets or target pathways (Schmiegelow, 2009; Mik-
kelsen et al, 2011). However, conflicting results exist as to
whether there are unambiguous candidate pharmacogenetic
predictors for MTX clearance and toxicity (de Jonge et al,
2005; Trevino et al, 2009a; Radtke et al, 2013).
Methotrexate is a folate analogue that enters the cells by
both passive diffusion and the solute carrier 19A1 (SLC19A1,
formerly known as the reduced folate carrier 1, RFC1)
(Nersting & Schmiegelow, 2009; Mikkelsen et al, 2011). Inside
the cell MTX is converted to its active polyglutamate forms
(methotrexate polyglutamates, MTXPGs) by the enzyme
folylpolyglutamate synthase (FPGS) (Mikkelsen et al, 2011).
The primary action of MTX is the inhibition of the enzyme
dihydrofolate reductase (DHFR), which is responsible for
converting folate to its active, chemically reduced, tetrahy-
drofolate form (Mikkelsen et al, 2011). Several other enzymes
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involved in the folate pathway influence the effect of MTX,
including methylenetetrahydrofolate reductase (MTHFR),
methylenetetrahydrofolate dehydrogenase (MTHFD1), thymi-
dylate synthetase (TYMS), serine hydroxymethyltransferase 1
(SHMT1), 5-methyltetrahydrofolate-homocisteine methyl-
transferase (MTR) and 5-methyltetrahydrofolate-homociste-
ine methyltransferase reductase (MTRR) (Mikkelsen et al,
2011). MTXPGs induce stronger inhibition of the target
enzymes (TYMS and DHFR) and further inhibit key enzymes
in the de novo purine synthesis pathway (Mikkelsen et al,
2011). The degradation of MTXPGs to MTX is catalysed by
the enzyme gamma-glutamyl hydrolase (GGH) (Mikkelsen
et al, 2011). Genetic variability in these metabolizing
enzymes, transporters and targets has already extensively
been studied because it can lead to an altered sensitivity to
MTX and thus exert clinically significant effects on the effi-
cacy and toxicity of MTX treatments in children with ALL
(Cheok & Evans, 2006; Faganel Kotnik et al, 2011; Gervasini
& Vagace, 2012). Hepatic uptake of MTX involves the solute
carrier organic anion transporter family, member 1B1
(SLCO1B1). SNPs in the SLCO1B1 gene have recently been
identified as important determinants of MTX pharmacoki-
netics (Trevino et al, 2009a; Mikkelsen et al, 2011; Radtke
et al, 2013; Ramsey et al, 2013). Inside the hepatocytes MTX
is converted to 7-hydroxy-methotrexate (7-OH-MTX), a
metabolite that contributes to the effect and toxicity of MTX
(Walling, 2006; Yarlagadda & Perazella, 2008). Systemic
MTX is eliminated primarily by renal excretion. The solute
carrier family 22 (organic anion transporter), member 8
(SLC22A8) is one of the renal transporters that have an
affinity for MTX (Mikkelsen et al, 2011). MTX is also a sub-
strate of ABCB1, which is a member of the ATP-binding cas-
sette transporter family [ATP-binding cassette, sub-family B
(MDR/TAP), member 1] and mediates the efflux of MTX
across the cell membrane (Mikkelsen et al, 2011).
The AT rich interactive domain 5B gene (ARID5B, also
termed MRF2) encodes a member of the ARID family of
transcription factors and is a novel susceptibility factor for
childhood B-cell ALL (Trevino et al, 2009b; Healy et al,
2010; Lautner-Csorba et al, 2012). A relationship between
ARID5B and ALL treatment response in the context of a
frontline ALL clinical trial and an association between
ARID5B SNP genotypes and greater MTXPGs accumulation
of the leukaemic cells have already been observed (Trevino
et al, 2009b; Xu et al, 2012), but no association between
ARID5B and the pharmacokinetics or toxicity of MTX has
previously been reported.
The aim of the present study was to investigate the influ-
ence of SNPs in genes of the folate metabolic pathway, trans-
porter molecules and transcription proteins on the
pharmacokinetics and toxicity of MTX and 7-OH-MTX in
children with ALL. A total of 63 SNPs of 14 genes were
selected and evaluated in an integrated approach, including
all relevant covariates and factors in a paediatric point of
view.
Methods
Patients, pharmacokinetics and toxicity
The DNA and clinical data were collected retrospectively
from 118 children with ALL who were treated with HD-MTX
at the 2nd Department of Paediatrics, Semmelweis University
(Budapest, Hungary) between 1998 and 2011. All children
who underwent HD-MTX treatment and whose clinical data
and DNA could be obtained were included. The mean
patient age was 64 years (range: 11–18 years). All patients
were of Hungarian (Caucasian) ethnicity. The study was
approved by the Hungarian Scientific and Research Ethics
Committee of the Medical Research Council. Informed con-
sent was obtained from all participants and their parents or
legal guardians before inclusion in the study.
Each patient was treated according to two Berlin-Frankf€urt-
M€unster (BFM) ALL protocols [ALL-BFM 95 (25 patients –
5 g/m2) or ALL intensive chemotheraphy (IC)-BFM 2002 (23
patients – 5 g/m2 and 70 patients – 2 g/m2)] (ALL IC-BFM
Trial Steering Committee, 2002; Moricke et al, 2008). Intrave-
nous HD-MTX infusions were administered in the consolida-
tion phase of chemotherapy. According to the protocols,
HD–MTX was administered as a 24-h continuous intravenous
infusion four times during the consolidation phase of chemo-
therapy. Pre-hydration with alkalinized intravenous fluids was
applied at 1500 ml/m2/12 h before HD-MTX treatment, con-
current hydration was applied at 3000 ml/m2/24 h and post-
hydration was applied at 3000 ml/m2/24 h in the 48–72 h
following HD-MTX treatment. According to the protocols,
calcium-leucovorin rescue was initiated with a 15 mg/m2 dose
at 42 h after the start of the HD-MTX infusion, and given twice
more, at 48 and 54 h after the infusion. If the serum MTX level
had not decreased below 025 lmol/l at 48 h, extended leu-
covorin rescue was given. We documented those cases in which
the MTX levels at 48 h were >025 or >05 lmol/l.
Complete sets of pharmacokinetic data on four courses of
MTX treatment were available for 113 patients and pharma-
cokinetic data on two courses of MTX treatment were avail-
able for an additional four patients, while three courses of
MTX treatment were available from one patient. A total of
463 MTX courses were included in the analysis.
Patients’ characteristics and data regarding the pharmaco-
kinetics and toxicity of MTX were collected from the patients
charts (Table I).
The MTX and 7-OH-MTX serum levels were measured
from blood samples at 24, 36 and 48 h after the beginning of
the infusion (24, 36 and 48 h). Additional MTX serum mea-
surements were performed at 66, 72, 96 and 120 h if the
MTX level was measurable after 48 h. The cerebrospinal fluid
(CSF) MTX levels were measured 24 h after the start of the
infusion. The MTX and 7-OH-MTX levels were estimated
either by high-performance liquid chromatography (HPLC)
in the Pharmacokinetic Laboratory of the National Oncology
Institute (Budapest, Hungary) or by enzyme immunoassay
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(EIA) at the 2nd Department of Paediatrics, Semmelweis
University (Budapest, Hungary). As serum MTX or 7-OH-
MTX measurements were available at only 3 time points per
MTX course in most of the patients, MTX or 7-OH-MTX
clearance could not be calculated appropriately. Hence we
investigated the simultaneous alteration of the MTX or
7-OH-MTX levels at 24 h + 36 h + 48 h. The area under the
concentration-time curve (AUC) of MTX and 7-OH-MTX
was calculated according to the trapezoidal rule (Hegyi et al,
2012; Csordas et al, 2013). MTX and 7-OH-MTX levels at
24 h + 36 h + 48 h represented simultaneously as a multi-
variate response variable (MTX 24 h + 36 h + 48 h and
7-OH-MTX 24 h + 36 h + 48 h) and the AUC of MTX and
7-OHMTX were used for characterizing the pharmacokinet-
ics of MTX and 7-OH-MTX.
The evaluation of toxicity was performed as previously
reported (Csordas et al, 2013). Serum haemoglobin levels,
platelet counts, white blood cell counts, granulocyte counts,
transaminase levels [alanine aminotransferase (ALT), gamma-
glutamyltransferase (GGT)], creatinine levels, total protein
levels and bilirubin levels were measured from the blood
samples before the HD-MTX infusion (day 0) and on days 1,
2 and 7 after each HD-MTX infusion. Toxicity values were
evaluated by applying the National Cancer Institute Com-
mon Terminology Criteria for Adverse Events version 4.0
scoring system (http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.
03_2010-06-14_QuickReference_5x7.pdf) and the most severe
(grade 3–4) toxicity was analysed.
Candidate gene selection and genotyping
The process of gene selection and genotyping were conducted
according to our previous report (Lautner-Csorba et al,
2012). We selected 14 candidate genes from the literature,
based on the results of genome-wide association studies, can-
didate gene association studies and other studies in which
the investigated pathways could also be important for MTX.
We searched for SNPs in these 14 genes in online databases.
The selection criterion was: minor allele frequency >10%.
The SNPs were prioritized according to their published role
in the pharmacokinetics of MTX, and their estimated func-
tionality. In some cases tag SNPs were selected from the
HapMap database (http://hapmap.ncbi.nlm.nih.gov/). A total
of 63 SNPs were selected. Detailed information regarding the
selected genes and SNPs is shown in Table SI.
Genomic DNA from the children was obtained retrospec-
tively from whole peripheral blood samples taken in remission
using QIAmp DNA Blood Midi Kit (Qiagen, Hilden, Ger-
many) according to the manufacturer’s instructions. Genotyp-
ing was carried out by Sequenom iPLEX Gold MassARRAY
technology at the McGill University and Genome Quebec
Innovation Centre, Montreal, Canada. Only SNPs with a
genotyping call rate over 90% were included in the analysis.
Statistical analysis
Allele frequencies were calculated by allele counting (Table
SII, which contains the genotype and allele frequency of the
Table I. Patient characteristics and toxicity* of HD-MTX treatments.
Patient characteristics Value
Total number of patients 118
Gender n (%)
Male 74 (627)
Female 44 (373)
Mean age at diagnosis in years (range) 64 (11–18)
Protocol n (%)
ALL-BFM 95 25 (212)
ALL IC-BFM 2002 93 (788)
Risk group n (%)
Standard 38 (322)
Medium 60 (508)
High 20 (17)
Immunophenotype n (%)
B-ALL 95 (805)
T-ALL 21 (178)
Biphenotype 2 (17)
MTX dose n (%)
5 g/m2
Number of patients treated 48 (407)
Number of MTX courses 178 (384)
2 g/m2
Number of patients treated 70 (593)
Number of MTX courses 285 (616)
Total number of MTX courses 463
Hepatotoxicity* n (%) (serum bilirubin level >50 lmol/l
on days 1–7)
5 g/m2
Number of MTX courses 7/172 (41)
2 g/m2
Number of MTX courses 5/279 (18)
Nephrotoxicity* n (%) (serum creatinine level >100 lmol/l
on day 7)
5 g/m2
Number of MTX courses 5/155 (32)
2 g/m2
Number of MTX courses 4/208 (19)
Granulocytopenia* n (%) (absolute neutrophil count <1 9 109/l
on day 7)
5 g/m2
Number of MTX courses 60/153 (392)
2 g/m2
Number of MTX courses 73/267 (273)
Hypoproteinaemia* n (%) (serum total protein level <60 g/l on
day 7)
5 g/m2
Number of MTX courses 22/149 (148)
2 g/m2
Number of MTX courses 18/206 (87)
HD, high dose; MTX, methotrexate; ALL, acute lymphoblastic leu-
kaemia.
*Toxicity is shown only if it was associated with the investigated
genetic variants.
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studied SNPs). Hardy-Weinberg equilibrium was tested by
using a chi-square goodness-of-fit test with an acceptable
cut-off value of P ≤ 005 (http://www.oege.org/software/
hwe-mr-calc.shtml). A SNP was excluded from the statistical
analysis if the frequencies of the wild type and variant alleles
deviated from the Hardy-Weinberg equilibrium requirement
(a total of 4 SNPs were excluded).
The relationships between the SNPs and the pharmacoki-
netics or toxicity of MTX were analysed by the R (version
2.15) program (R Development Core Team, 2010). Patient
characteristics, prognostic factors (gender, age, ALL immuno-
phenotype, risk group and treatment protocol), the adminis-
tered HD-MTX dose (2 or 5 g/m2), the number (1–4) of
sequential HD-MTX courses of each patient, the method of
MTX measurement (HPLC or EIA) and the SNPs were all
included as explanatory variables in the analysis.
In the first step, random forest (RF) method with the cfor-
est function of the package party (version 1.0-6.) imple-
mented in the R software was applied to calculate variable
importance measures because of the large number of explan-
atory variables and the relatively small sample size (Strobl
et al, 2008; Hothorn et al, 2013). The number of randomly
preselected variables (mtry) was set to the square root of the
number of observations (√n). The number of trees (ntree)
was 1000. The value of the test statistic or 1  P value that
must be exceeded in order to implement a split (mincriteri-
on) was set to 08. The RF was used to select the important
variables from all explanatory variables for further analyses.
Variables were considered informative or important if their
value was above the absolute value of the lowest negative-
scoring variable (Strobl et al, 2009).
In the second step, we built classification and regression
trees (CART) with the ctree function of the package party
(Hothorn et al, 2006). The value of test statistic (1  P
value) that must be exceeded in order to implement a split
(mincriterion) was set to 095. The minimum sum of weights
in a node in order to be considered for splitting (minsplit)
was 2. The minimum sum of weights in a terminal node
(minbucket) was 1. The CARTs were built with the selected
explanatory variables to generate clinical decision rules and
to explore the relationship between the response and the
explanatory variables (Strobl et al, 2009).
In the last step, the general linear mixed model (GLMM,
testing the relationship between SNPs and the logarithmic
transformed serum levels of MTX and 7-OH-MTX) and gen-
eralized linear mixed model (GzLMM) with logit link func-
tion for binomial data (testing the relationship between SNPs
and toxicity) were applied to prove the significance of the
selected variables and their interactions by the CART and to
estimate effect sizes. GLMM and GzLMM enabled the corre-
lated nature of the data (four measurements for each patient)
to be taken into account (Pinheiro & Bates, 2000; Bates et al,
2012). The proportion of variation in the response variable
that is explained by the mixed models [marginal and condi-
tional R2, R2GLMMðmÞ and R
2
GLMMðcÞ] was calculated according
to Nakagawa and Schielzeth (2013). Relationships between
SNPs and toxicity were analysed separately according to the
administered MTX dose (in patients who received 5 g/m2
and in patients who received 2 g/m2 MTX). Model effects
were tested together based on their F values (GLMM) and
likelihood ratio tests in case of generalized models. All factors
and potential interactions were evaluated, with the cut-off
for inclusion being P < 005. The 95% confidence intervals
(CIs) of odds ratios (OR) were calculated by the Wald’s
method (Agresti, 2002).
The statistical power of the linear mixed-effect model
analyses was calculated with the Pwr function of the package
nlmeU (version 0.70-3., Galeczki & Burzykowski, 2013). The
power of our models ranged between 62% and 86%.
Results
MTX and 7-OH-MTX levels
In the case of the serum MTX and 7-OH-MTX levels, RF
analysis was conducted according to the mean MTX and
7-OH-MTX levels at the defined time points (24, 36 and
48 h separately).
In the case of serum MTX levels or AUC of MTX, the
administered MTX dose, ALL phenotype, risk group, patient
age, rs2612100, rs2236225, rs1004474, rs9967368, rs7499, rs708
9424, rs10821936, rs4506592, rs1076991, rs745686, rs4948496,
rs1801394, rs4363657, rs4149056 and rs1202179 seemed to be
associated with one or more of the mean serum MTX levels
(24 and/or 36 and/or 48 h) and/or with the AUC of MTX.
The classification and regression trees (CARTs) of the
serum MTX levels and the AUC of MTX were built with the
use of these selected explanatory variables. The MTX levels at
the defined time points were represented simultaneously as a
multivariate response variable (MTX 24 h + 36 h + 48 h).
The CART of the serum MTX levels (24 h + 36 h + 48 h)
shows that the administered MTX dose (5 or 2 g/m2) had
the strongest effect on the serum MTX levels (P < 0001,
Fig 1A). In patients who received 2 g/m2, ARID5B rs4948496
showed a significant association with the serum MTX levels
(P = 001). Patients with the CC genotype were found to
have higher serum MTX levels than patients with the CT+TT
genotype. In patients who received 2 g/m2 MTX and had the
ARID5B rs4948496 CT+TT genotype, the SLCO1B1
rs4149056 also showed a significant association with the
serum MTX levels (P < 0001, Fig 1A). Patients with the TT
genotype had lower serum MTX levels than patients with
CT+CC genotype. In patients who received 2 g/m2 MTX
associations between both SNPs and serum MTX levels were
confirmed with the general linear mixed models (GLMM)
(rs4948496: P = 0039, rs4149056: P = 0004). In the GLMM
the rs4948496 + rs4149056 genotypes explained 6%, 107%
and 9% interindividual variability [R2GLMMðmÞ] in the MTX
levels at 24, 36 and 48 h [R2GLMMðcÞ was 25%, 371% and
227% at 24, 36 and 48 h].
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In patients who received 2 g/m2 MTX and had the
ARID5B rs4948496 CC genotype, high (>025 lmol/l) MTX
levels at 48 h were found more frequently (CC versus CT+TT
genotype: 61% vs. 39%, P = 0044). However, in the case of
the calculated AUC of MTX, the administered MTX dose (5
or 2 g/m2) showed the strongest and only effect according to
the CART and the GLMM (P < 0001).
In the case of the CSF MTX levels only patient age and
the rs4948502 seemed to be associated with the CSF MTX
levels according to the RF, however none of the explanatory
variables was proved to be associated with the CSF MTX lev-
els according to the CART and GLMM.
Serum 7-OH-MTX levels or AUC of 7-OH-MTX seemed
to be associated with the administered MTX dose, ALL
phenotype, patient age, rs9967368, rs10841769, rs7499,
rs2235013, rs4451422, rs1202179, rs4948487, rs4948496,
rs2518463, rs4948502, rs12759827, rs10106 and rs1801394
according to the RF. The CARTs of the AUC of 7-OH-MTX
and serum 7-OH-MTX levels were built with the use of these
explanatory variables. The serum 7-OH-MTX levels at the
defined time points were represented simultaneously as a mul-
tivariate response variable (7-OH-MTX 24 h + 36 h + 48 h).
The CART of the serum 7-OH-MTX levels
(24 h + 36 h + 48 h) showed similar results to the CART of
the serum MTX levels (Fig 1B). The administered MTX dose
(5 or 2 g/m2) had the strongest effect on the serum 7-OH-
MTX levels (P < 0001). In both groups ARID5B rs4948502
showed significant associations with the serum levels
(P = 0015 and P < 0001), which was also confirmed by the
GLMM (5 and 2 g/m2, P = 0003 and P = 0033).
In the patients who received 5 g/m2 MTX the rs4948502
accounted for 126%, 14% and 163% of interindividual vari-
ability [R2GLMMðmÞ] in the 7-OH-MTX levels at 24, 36 and
48 h [R2GLMMðcÞ was 484%, 58% and 453% at 24, 36 and
48 h]. In those patients who received 2 g/m2 MTX the the
rs4948502 accounted for 15%, 93% and 129% of interindi-
vidual variability [R2GLMMðmÞ] in the 7-OH-MTX levels at 24,
36 and 48 h [R2GLMMðcÞ was 56%, 612% and 517% at 24, 36
and 48 h].
However, the associations between the SNP and serum
levels in the two groups are not unambiguous. Higher serum
7-OH-MTX levels were found in patients who received 2 g/
m2 MTX and had the ARID5B rs4948502 CC genotype,
whereas in patients who received 5 g/m2 MTX the CC geno-
type was associated with lower serum 7-OH-MTX levels (in
comparison with patients with the CT+TT genotype). In the
patients who received 5 g/m2 MTX and had the ARID5B
rs4948502 CT or TT genotype an additional SNP, ARID5B
rs4948496, showed a significant association with the 7-OH-
MTX levels according to the CART (P = 0011) but this was
not confirmed by the GLMM.
The result of the CART of the calculated AUC of 7-OH-
MTX was similar to the CART of the serum 7-OH-MTX lev-
els (Fig 1C). The ARID5B rs4948502 showed a significant
association with the AUC of 7-OH-MTX in both groups (5
and 2 g/m2: P < 0001 separately), which was confirmed by
the GLMM (5 and 2 g/m2: P < 0001 and P = 0013).
In the patients who received 5 g/m2 MTX the rs4948502
accounted for 141% interindividual variability [R2GLMMðmÞ] in
the AUC of 7-OH-MTX [R2GLMMðcÞ was 52%]. In those
patients who received 2 g/m2 MTX the rs4948502 accounted
for 189% interindividual variability [R2GLMMðmÞ] in the AUC
of 7-OH-MTX [R2GLMMðcÞ was 615%].
The ARID5B rs4948496 showed a significant association
with the AUC 7-OH-MTX in patients who received 5 g/m2
MTX and had the ARID5B rs4948502 CT or TT genotype
(P = 0003), but this was confirmed by the CART only.
Toxicity of HD-MTX treatments
Hepatotoxicity (serum bilirubin level >50 lmol/l) on days
1–7 seemed to be associated with the administered MTX
dose, patient age, rs3768142, rs11045819, rs7499, rs1544105,
rs17328763, rs11045818, rs2853523, rs10106, rs4451422,
rs745686, rs4948502, rs2276299 and rs2853533 according to
the RF analysis. The CART showed significant associations
between hepatotoxicity and the SLC19A1 rs7499 (P = 0003)
and ARID5B rs4948502 (P = 0007) in patients who received
5 g/m2 MTX (Fig 2A). Toxic bilirubin levels did not occur
in cases (n = 13) with the SLC19A1 rs7499 AA genotype and
the ARID5B rs4948502 TT genotype.
Nephrotoxicity (serum creatinine level >100 lmol/l) on
days 1–7 seemed to be associated with the MTX levels at 36 h,
rs4149183, rs1544105, rs1004474 and rs3212713 according to
Fig 1. (A) Classification and regression tree of the serum MTX levels (24 h + 36 h + 48 h). Circles (1, 3, 5) represent the explanatory variables
that are significantly associated with the serum methotrexate (MTX) levels. The different subgroups of the explanatory variables are shown along
the lines. Rectangles (2, 4, 6, 7) represent the mean MTX levels at 24 h + 36 h + 48 h simultaneously: y = (mean MTX level at 24, 36, 48 h),
and the number of the observations in the adequate group (n = number of MTX cycles). Results are specified in the text. (B) Classification and
regression tree of the serum 7-OH-MTX levels (24 h + 36 h + 48 h). Circles (1, 2, 3, 7) represent the explanatory variables that are significantly
associated with the serum 7-hydroxy-methotrexate (7-OH-MTX) levels. The different subgroups of the explanatory variables are shown along the
lines. Rectangles (4, 5, 6, 8, 9) represent the mean 7-OH-MTX levels at 24 h + 36 h + 48 h simultaneously: y = (mean 7-OH-MTX level at 24,
36, 48 h) and the number of the observations in the adequate group [n = number of methotrexate (MTX) cycles]. Results are specified in the
text. (C) Classification and regression tree of the AUC of 7-OH-MTX. Circles (1, 2, 3, 7) represent the explanatory variables that are significantly
associated with the area under the concentration-time curve (AUC) of 7-hydroxy-methotrexate (7-OH-MTX). The different subgroups of the
explanatory variables are shown along the lines. Rectangles (4, 5, 6, 8, 9) represent the mean AUC of 7-OH-MTX: y = (mean AUC of 7-OH-
MTX) and the number of the observations in the adequate group [n = number of methotrexate (MTX) cycles]. Results are specified in the text.
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the RF analysis. The CART showed a significant association
between the SLC22A8 rs4149183 and nephrotoxicity in
patients who received 5 g/m2 MTX (Fig 2B). Nephrotoxicity
was found significantly more frequently in patients with CC
genotype versus CT+TT genotype (25% vs. 1%, P = 0001).
According to the CART, among patients with CC genotype,
(A)
(B)
(C)
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those aged >92 years had a 100% occurrence of nephrotoxi-
city versus a 0% occurrence in patients aged <92 years
(P = 0022). In the cases of hepatotoxicity and nephrotoxicity,
generalized linear mixed models (GzLMM) were not carried
out, because the occurrences of these side-effects were <5%.
Hypoproteinaemia (serum total protein level <60 g/l) on
days 1–7 seemed to be associated with the risk group, the
rs4948487, rs1076991 and the serum 7-OH-MTX levels at
36 h according to the RF. The CART showed significant
associations between hypoproteinaemia and the ARID5B
rs4948487 (P = 0004) and the MTHFD1 rs1076991
(P < 0001) in patients who received 2 g/m2 MTX (Fig 2C).
GzLMM was not carried out because hypoproteinaemia
occurred in 18 cases only. However the trend that hypopro-
teinaemia occurred more frequently in patients with the
ARID5B rs4948487 AA genotype and in patients with the
MTHFD1 rs1076991GG genotype is represented in Table II.
Granulocytopenia (absolute neutrophil granulocyte count
<1 9 109/l) on days 1–7 seemed to be associated with the risk
group, administered MTX dose, rs1979277, rs2235013,
rs9967368, rs10821936, rs4948502, rs4506592, rs7089424,
rs1801394, rs1544105, rs4948496 and rs3768142 according to
the RF analysis. The CART and the GzLMM showed a signifi-
cant association between granulocytopenia and the MTR
rs3768142 in patients who received 2 g/m2 MTX [GG versus
GT+TT genotype: 56% vs. 23%, OR: 592 (95% CI: 203–
1727), P = 0001]. Granulocytopenia occurred significantly
more frequently after the last (4th) MTX cycle than after the
others (cycles 1–3); OR: 348 (95% CI: 140–864), P = 0007.
Discussion
The therapy of ALL is based on risk-adapted protocols with
a 5-year survival rate of 84-94% in developed countries (Pui
et al, 2011). Current ALL trials focus on improving not only
the efficacy of the treatment but also the quality of life of the
patients (Pui et al, 2011). Patients with higher risk of relapse
are treated more intensively, with the potential risk for toxic
side effects. The major clinical challenge is to balance the
efficacy of HD-MTX therapy against its toxicity (Schmiege-
low, 2009; Faganel Kotnik et al, 2011). HD-MTX plays an
important role in the consolidation therapy of ALL in many
treatment regimens worldwide. However, there is a large
interpatient variability in the pharmacokinetics and toxicity
of the drug (Schmiegelow, 2009; Mikkelsen et al, 2011; Csor-
das et al, 2013). If we had reliable biomarkers we could iden-
tify those patients with increased risk of treatment failures or
specific toxicities and could adjust the HD-MTX treatment
individually.
In the present study we investigated whether SNPs in
genes of the folate metabolic pathway, transporter molecules
and transcription proteins modify the pharmacokinetics or
toxicity of MTX and 7-OH-MTX in children with ALL. A
total of 63 SNPs of 14 genes were selected and evaluated in a
multivariate analysis.
The SNPs of the ARID5B gene (rs4948502, rs4948496 and
rs4948487) showed significant associations with the serum
MTX (in patients who received 2 g/m2 MTX) and 7-OH-
MTX levels and with the development of hypoproteinaemia
in our study. The CC genotype of the rs4948496 was associ-
ated with higher serum MTX levels; however the associations
between the CC genotype of the rs4948502 and the 7-OH-
MTX levels were not unambiguous. In patients who received
2 g/m2 MTX it was associated with higher serum 7-OH-MTX
levels, whereas lower serum 7-OH-MTX levels were found in
patients who received 5 g/m2 MTX and had the CC genotype.
The ARID5B gene encodes a transcriptional factor that plays a
role in the cell-growth and the differentiation of B-lympho-
cyte progenitors (Trevino et al, 2009b). SNPs of this gene
Table II. Contingency table of the hypoproteinaemia developed
according to the rs4948487 and rs1076991* genotypes.
Hypoproteinaemia
(<60 g/l)
rs4948487 (ARID5B)
rs1076991
(MTHFD1)
AA
[n (%)]
AC+CC
[n (%)]
GG
[n (%)]
AG+AA
[n (%)]
Yes 8 (24) 7 (4) 9 (23) 8 (5)
No 25 (76) 156 (96) 31 (77) 151 (95)
HD, high dose; MTX, methotrexate.
n (%) = number (percent) of MTX courses.
*In patients who received 2 g/m2 HD-MTX.
Fig 2. (A) Classification and regression tree of hepatotoxicity on days 1–7 in patients who received 5 g/m2 MTX. Circles (1, 2) represent the
explanatory variables that are significantly associated with the development of hepatotoxicity. The different subgroups of the explanatory variables
are shown along the lines. Rectangles (3, 4, 5) represent the frequency of developed toxicity y = (frequency of no toxicity, frequency of toxicity)
in the different groups, and the number the observations in the adequate group [n = number of methotrexate (MTX) cycles]. Results are speci-
fied in the text. (B) Classification and regression tree of nephrotoxicity on days 1–7 in patients who received 5 g/m2 MTX. Circles (1, 2) represent
the explanatory variables that are significantly associated with the development of nephrotoxicity. The different subgroups of the explanatory vari-
ables are shown along the lines. Rectangles (3, 4, 5) represent the frequency of developed toxicity: y = (frequency of no toxicity, frequency of tox-
icity) in the different groups, and the number the observations in the adequate group [n = number of methotrexate (MTX) cycles]. Results are
specified in the text. (C) Classification and regression tree of hypoproteinaemia on days 7 in patients who received 2 g/m2 MTX. Circles (1, 3)
represent the explanatory variables that are significantly associated with the development of hypoproteinaemia. The different subgroups of the
explanatory variables are shown along the lines. Rectangles (2, 4, 5) represent the frequency of developed toxicity: y = (frequency of no toxicity,
frequency of toxicity) in the different groups and the number the observations in the adequate group [n = number of methotrexate (MTX)
cycles]. Results are specified in the text.
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have previously been associated with higher susceptibility to
ALL and B-hyperdiploid subtype of ALL and to contribute to
racial disparities in the incidence and treatment outcome of
ALL (Trevino et al, 2009b; Lautner-Csorba et al, 2012; Xu
et al, 2012). Genetic variations of ARID5B have also been
linked to greater MTXPGs accumulation in patients with ALL
(Trevino et al, 2009b). However this is the first study to
investigate the relationship between the ARID5B gene and the
pharmacokinetics and toxicity of MTX. The exact role of this
gene on MTX levels and toxicity needs further investigations.
The rs4149056 of the SLCO1B1 gene showed significant
association with serum MTX levels in patients who received
2 g/m2 MTX according to our study. Lower MTX levels were
found in patients with the SLCO1B1 rs4149056 TT genotype
than in patients with CT+CC genotype. The SLCO1B1 gene
encodes an organic anion transporter that is localized at the
sinusoidal membrane of hepatocytes and is responsible for
the hepatic uptake of the drug (Trevino et al, 2009a; Radtke
et al, 2013). Trevino et al (2009a) described that the
SLCO1B1 rs4149056 was associated with MTX clearance and
gastrointestinal toxicity. More recently, the association
between the SLCO1B1 rs4149056 and MTX clearance was
also clearly replicated (Radtke et al,2013; Ramsey et al,
2013). Other SNPs of the SCLO1B1 gene (rs11045879 and
rs4149081) have also been associated with high MTX plasma
levels in former studies (Lopez-Lopez et al, 2011, 2013). Our
results confirm the studies that suggest SLCO1B1 is a novel
predictor for MTX clearance and toxicity (Trevino et al,
2009a; Lopez-Lopez et al, 2011, 2013; Ramsey et al, 2013).
The most common side effects following HD-MTX therapy
are hepato-, nephro- and myelotoxicity. Conflicting results exist
whether genetic variants in genes that encode proteins of the
folate pathway contribute to the development of MTX toxicity.
Our results indicate that hepatotoxicity was significantly
associated with the SLC19A1 rs7499. This is the first study to
show an association between this genetic variant of the
SLC19A1 gene and HD-MTX toxicity. However, the most fre-
quently studied polymorphism of SLC19A1, rs1051266,
showed no association with either the MTX levels or the
developed toxicity in the present study. The relationship
between the genetic variants of the SLC19A1 gene and the
serum MTX levels has previously been shown (Laverdiere
et al, 2002; Lopez-Lopez et al, 2013). In former studies the
rs1051266 was associated with gastrointestinal, bone marrow
and hepatotoxicity (Kishi et al, 2007; Gregers et al, 2010; Yee
et al, 2010). A former study also reported an association
between the rs1051266 and a decreased risk for leucopenia in
ALL/malignant lymphoma patients (Faganel Kotnik et al,
2011). On the other hand, some studies have not confirmed
any association between SLC19A1 and HD-MTX toxicity
(Kishi et al, 2003; Huang et al, 2008; Faganel Kotnik et al,
2010).
Our CART analysis showed significant association between
the development of nephrotoxicity and the SLC22A8
rs4149183 in patients who received 5 g/m2 MTX. Nephrotox-
icity occurred in each patient aged >92 years with the
SLC22A8 rs4149183 CC genotype. Higher MTX levels, slower
clearance and higher occurrence of MTX toxicity have been
reported in older patients in the majority of the published
studies, including a previous one from our group (Groninger
et al, 2004; Plard et al, 2007; Csordas et al, 2013). SLC22A8
is mainly expressed in the kidneys and to a lesser extent in
the brain (Rizwan & Burckhardt, 2007). Genetic variants of
SLC22A8 were significantly associated with MTX clearance in
a previous study (Lopez-Lopez et al, 2013).
In the present study, granulocytopenia was associated with
the MTR rs3768142 in patients who received 2 g/m2 MTX.
This is the first study to report a significant association
between this genetic variant of the MTR gene and the devel-
opment of HD-MTX toxicity. Genetic variants of the MTR
gene are less commonly studied, but the rs1805087 SNP of
this gene has previously been associated with gastrointestinal
and haematologic toxicity of HD-MTX in osteosarcoma
patients (Patino-Garcia et al, 2009). However, controversial
results also exist; in another study the same SNP showed no
significant association with the toxicity of HD-MTX therapy
in patients with ALL (Faganel Kotnik et al, 2011).
Beside the SNP of the ARID5B gene, the rs1076991 of the
MTHFD1 gene was associated with the development of hypo-
proteinaemia after the HD-MTX treatments in patients who
received 2 g/m2 MTX. MTHFD1 plays a key role in the folate
metabolism (de Jonge et al, 2005). Another genetic variant
(rs2236225) of the MTHFD1 gene has been shown to reduce
the odds of hepatotoxicity, but was also related to anaemia
after HD-MTX treatments in ALL/osteosarcoma patients
(Erculj et al, 2012; Windsor et al, 2012). The MTHFD1
rs1076991 has been associated with congenital neural tube
defect (Greene et al, 2009), but to date no association with
HD-MTX toxicity has been reported.
Some limitations of our study need to be considered. It
was a retrospective study with a modest sample size. Data
were collected from patients who had received HD-MTX
according to their risk group. However, every possible influ-
ential variable was taken into account in our multivariate
analysis. The SNPs of the MTHFR and GGH genes were not
included in the present study. However, some publications
have referred to the effect of the different genetic variations
of these genes on MTX pharmacokinetics and toxicity (Pan-
etta et al, 2010; Faganel Kotnik et al, 2011).
The strength of our study is that variable importance mea-
sures were made with RF analysis, which is a type of recur-
sive partitioning method, particularly well-suited when a
small sample size with large number of observations is given
(small n and large p problems) (Strobl et al, 2008, 2009). RF
variable importance measures, as compared to univariate
screening methods, cover the impact of each predictor vari-
able individually as well as in multivariate interactions with
other predictor variables. We used classification and regres-
sion trees to demonstrate our results. The results were vali-
dated by linear mixed models in each case.
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Our results should be interpreted as exploratory findings
that might serve for hypothesis generation. We believe that
our results might be useful in designing future pharmacoge-
netic studies. Our ongoing international collaboration is now
developing a MTX pharmacogenetic study (ALL IC-BFM
Trial Steering Committee 2009) in which we focus on
exploring the influence of different genetic variations on
MTX pharmacokinetics in a larger, randomized cohort.
Conclusion
Polymorphisms of the ARID5B gene were significantly associ-
ated with the serum levels and toxicity of MTX and its
metabolite, 7-OH-MTX. The present study confirms the pos-
sible role of SLCO1B1 as a pharmacogenetic predictor for
MTX pharmacokinetics. Novel genetic variants of the
SLC19A1, SLC22A8, MTR and MTHFD1 genes were shown
to be associated with the development of acute toxicity after
HD-MTX treatment. Further analysis and validation in a lar-
ger cohort is necessary to determine the predictive value of
these associations. An international collaboration is now
exploring this issue in a new ALL trial.
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